



**HAL**  
open science

# Single-Cell Technologies for the Study of Antibody-Secreting Cells

Matteo Broketa, Pierre Bruhns

► **To cite this version:**

Matteo Broketa, Pierre Bruhns. Single-Cell Technologies for the Study of Antibody-Secreting Cells. *Frontiers in Immunology*, 2022, 12, pp.821729. 10.3389/fimmu.2021.821729 . hal-03582460

**HAL Id: hal-03582460**

**<https://hal.sorbonne-universite.fr/hal-03582460>**

Submitted on 21 Feb 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



# Single-Cell Technologies for the Study of Antibody-Secreting Cells

Matteo Broketa<sup>1,2\*</sup> and Pierre Bruhns<sup>1\*</sup>

<sup>1</sup> Institut Pasteur, Université de Paris, INSERM UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France,

<sup>2</sup> Sorbonne Université, Collège doctoral, Paris, France

## OPEN ACCESS

### Edited by:

Ludvig M. Sollid,  
University of Oslo, Norway

### Reviewed by:

Ida Lindeman,  
Oslo University Hospital, Norway  
George Georgiou,  
University of Texas at Austin,  
United States

### \*Correspondence:

Matteo Broketa  
matteo.broketa@pasteur.fr  
Pierre Bruhns  
bruhns@pasteur.fr

### Specialty section:

This article was submitted to  
Systems Immunology,  
a section of the journal  
Frontiers in Immunology

**Received:** 24 November 2021

**Accepted:** 29 December 2021

**Published:** 31 January 2022

### Citation:

Broketa M and Bruhns P (2022)  
Single-Cell Technologies for the Study  
of Antibody-Secreting Cells.  
Front. Immunol. 12:821729.  
doi: 10.3389/fimmu.2021.821729

Antibody-secreting cells (ASC), plasmablasts and plasma cells, are terminally differentiated B cells responsible for large-scale production and secretion of antibodies. ASC are derived from activated B cells, which may differentiate extrafollicularly or form germinal center (GC) reactions within secondary lymphoid organs. ASC therefore consist of short-lived, poorly matured plasmablasts that generally secrete lower-affinity antibodies, or long-lived, highly matured plasma cells that generally secrete higher-affinity antibodies. The ASC population is responsible for producing an immediate humoral B cell response, the polyclonal antibody repertoire, as well as in parallel building effective humoral memory and immunity, or potentially driving pathology in the case of autoimmunity. ASC are phenotypically and transcriptionally distinct from other B cells and further distinguishable by morphology, varied lifespans, and anatomical localization. Single cell analyses are required to interrogate the functional and transcriptional diversity of ASC and their secreted antibody repertoire and understand the contribution of individual ASC responses to the polyclonal humoral response. Here we summarize the current and emerging functional and molecular techniques for high-throughput characterization of ASC with single cell resolution, including flow and mass cytometry, spot-based and microfluidic-based assays, focusing on functional approaches of the secreted antibodies: specificity, affinity, and secretion rate.

**Keywords:** plasma cell (PC), high-throughput technique, antibody secreting cell, droplet microfluidics, antibodies, B cells, functional bioassay

## INTRODUCTION

Antibody-secreting cells (ASC) are B cells that have differentiated following activation to secrete various soluble isotypes of their immunoglobulin receptor with the purpose of binding their target antigen throughout the body (1). ASC are predominantly generated within the germinal center reactions of secondary lymphoid organs (2), although extra-follicular responses may also generate ASC (3, 4). Following antigen exposure, parallel downregulation of major regulatory genes of activated B cells and upregulation of a unique ASC transcriptional program drives differentiation of B cells into early-ASC or plasmablasts. Several mechanisms have been proposed to govern ASC fate determination, but a unifying model has not yet been determined (1, 5). Plasmablasts are an unstable ASC intermediate that require input from a survival niche to persist long term. The bone marrow has been extensively studied as an ASC niche for its role in harboring ASC following


infection and immunization, however the majority of ASC are located in the gut-associated lymphoid tissue and produce IgA (6); the thymus has also recently emerged as an ASC niche (7, 8). The factors involved in early-ASC homing to survival niches are not completely understood. Plasmablasts may also be drawn towards sites of inflammation, where they act locally and acutely without persistence (9). Plasma cells are a long-lived ASC subset, characterized by reinforced expression of genes within the ASC differentiation network, responsible for secreting large quantities of antibodies from within their survival niches.

ASC are often considered the “apex” of B cell differentiation as they actualize antibody-mediated humoral immunity and are terminally differentiated. ASC contribute to both the acute humoral response to infection by rapidly generating early antibodies at sites of infection as well as later secreting higher affinity antibodies produced by germinal center reactions to aid in pathogen clearance and protective immunity. While the ASC response is advantageous during infection and when co-opted for immunization, emergence of ASC secreting antibodies towards self-antigens is a deleterious factor in many autoimmune disorders (10). Despite their importance, much is still unknown regarding ASC differentiation, selection, and

heterogeneity, particularly in autoimmune disorders. High throughput (HT) analyses of single cells are becoming more accessible, affordable, and common in literature concerning adaptive immune responses. This review will outline current and emerging HT techniques to characterize single ASC (Figure 1), with discussion of recent applications of these techniques to study the role of ASC in various pathologies as well as to expand understanding of fundamental ASC biology.

## FUNCTIONAL ANALYSES

The primary effector functions of ASC are mediated by their secreted antibodies, and thereby are characterized by a secreted phenotype. Polyclonal antibody responses of ASC are routinely assessed by sampling the serum or ASC-containing organs for binding antibodies and their global potency (11). Such methods provide an overview of the cumulative ASC response but are unable to interrogate ASC diversity. Techniques with single cell resolution are required to uncover the contributions of individual clones to the polyclonal ASC pool, the prevalence of specific groups of ASC, and the relationships between the factors



and markers that differentiate ASC. It should be noted that many other soluble effectors besides antibodies are also known to be secreted from ASC (12, 13), including various interleukins and transforming growth factor-beta one (TGF- $\beta$ 1), and HT functional assays may also be readily adapted to study the role of these soluble factors.

The topic of techniques for measuring single-cell protein secretion in immunology and their origins have been previously described (14, 15). Three general strategies are available for characterizing the secreted effectors of immune cells, each with applicability to ASC: spot-based assays, cytometry-based assays, and microfluidic-assays. These approaches globally share the strategy of isolating ASC, either by distance or compartmentalization, to ensure that “positive” loci or compartments reflect secretions or markers of single cells. Here we will focus on what these techniques offer to describe ASC behavior and highlight notable demonstrations of their use.

### Spot-Based Assays

Spot-based assays spatially distribute ASC by dilution and rely on localized membrane capture of secreted antibody or cytokine from ASC, followed by visualization with enzyme- or fluorophore-linked secondary antibodies (16, 17), termed enzyme-linked immunospot (ELISpot) and Fluorospot, respectively. The number of “spots” formed is indicative of the prevalence of ASC and/or antigen-specific ASC from a given sample. The strength of spot-based assays are their ease of use, robustness, and versatility between models (18, 19). Spot-based assays also directly observe secretion and therefore robustly identify ASC, in contrast to indirect-functional or molecular techniques where the ASC definition is inferred. However, ELISpot and Fluorospot are limited to the detection of only 1-2 or 1-4 soluble analytes, respectively, cannot precisely quantify secretion rates, and the ASC identified cannot be recovered for further analysis. ELISpot has seen extensive use in characterizing the ASC response during pathogenic infections (19, 20), in autoimmune disorders (21–23), and following immunization (24). Bonezi et al (25) recently used ELISpot to demonstrate the contribution of altered tryptophan metabolism to the hyper-abundance of ASC frequently seen during flavivirid infections, Dengue virus being the most common example.

### Cytometry-Based Assays

Flow cytometry and its derivative, fluorescence-activated cell sorting (FACS), have become a staple in investigations of B cells and ASC, allowing for relatively straightforward and rapid evaluation of multiple samples or experimental conditions (26, 27). Multicolor flow cytometry allows for immense diversity and depth of information gathered through the customization of antibody panels to target surface and intracellular markers. In contrast to ELISpot, flow cytometry can precisely identify the proportions of different ASC, B cell, and lymphocyte populations in each sample. Flow cytometry and ELISpot are frequently used in concert to measure global changes in the proportion of ASC and other B cells and the robustness and antigen-specificity of the ASC response, respectively (28, 29).

Human ASC are often defined in flow cytometry as larger cells with CD27 and CD38<sup>high</sup> expression among CD3<sup>-</sup> CD20<sup>-</sup> cells, and may be subdivided by expression of CD138, CD19, CD45, CD81, HLA-DR, and immunoglobulin isotypes (30–33). Plasma cells secreting human IgA or IgM, but not IgG, express surface immunoglobulin and may be identified by direct surface staining (34, 35). Local capture of IgG antibodies secreted by ASC onto their surface has been proposed to identify human IgG-secreting ASC by flow cytometry, using CD45 as a membrane anchor onto which IgG antibodies are captured by their constant region (Fc) (36), but has not yet been widely used. Surface markers and soluble effectors, namely antibodies and cytokines, not expressed at the cell membrane may be assessed using cell permeabilization and fixation to allow labelling reagents access within the cell; such intracellular staining normally precludes downstream assessment of cells by other functional or molecular methods. However, Price et al (37) demonstrated the feasibility to molecularly characterize ASC following intracellular staining for both antibody isotype as well as antibody specificity using tetramer constructs of antigens bound to fluorophore-conjugated streptavidin. Alternatively, early IgG-expressing ASC (IgG-ASC) often continue to bear their antibodies at the cell membrane, and surface staining for antibody isotype and antigen-specificity with tetramers offers a simpler method for isolating such IgG-ASC, though represents a restricted view of the whole IgG-ASC population (38, 39). Flow cytometry is also a valuable tool for scouting potential novel markers of ASC subsets (40). The use of intracellular tracing dyes further allows for assessment of ASC proliferation, as Scharer et al (41) have applied to ASC emergence from activated B cells.

Flow cytometry has identified ASC and ASC subsets in the context of autoimmune disorders and their contributions to acute and chronic disease states (42–45), and the ASC response to natural infection, as recently shown by Woodruff et al (46) in the context of COVID-19. The authors showed by flow cytometry a predominance of extrafollicularly-activated ASC in circulation, based on varied expression of CD11c, CXCR5, and CD21, and demonstrate its effect on infection morbidity. Noticeably, distinction between ASC derived from germinal centers or extrafollicularly is not possible with most other functional assays and is often overlooked. Application of FACS to *in vitro* models of ASC differentiation (47) and survival (48, 49) also highlights the ability of flow cytometry to distinguish ASC subpopulations. FACS isolation of populations of interest may be followed by a spot-based assay to query the subsequent prevalence of ASC within those populations (50–52).

It should be noted that current cytometric-gating strategies for ASC populations have not been demonstrated to completely define all ASC without exclusion of rarer phenotypes. Strategies often vary considerably, utilize a unique marker that may not be ASC-identifying in all contexts, or rely on intracellular staining of transcription factors (31, 53). ASC are distinct in their transcriptional regulation compared to other B cells, and the transcription factors IRF4, BLIMP-1, and XBP1 are ideal for complete identification of ASC (1, 53). Indeed, BLIMP1-YFP

mice have been invaluable to studying ASC differentiation, behavior, and transcriptional regulation (54, 55). IRF4-based labelling has similarly been used to identify differentiating human plasma cells following influenza vaccination (56).

Mass cytometry is based on a similar principle as flow cytometry, using heavy metal ions instead of fluorophores to distinguish the antibodies in the cytometry panel. Glass et al (57) utilized multiple mass cytometry panels to characterize over 350 B cell surface markers, combined with analyses of isotype usage, BCR sequence, metabolic profile, biosynthesis activity, and signaling response, which together constitute an expansive single-cell atlas of human B cells. An additional mass cytometry panel targeting enzymes associated with different metabolic pathways (58) found plasma cells to be highly metabolically active, and further subdivisible based on transcriptional activity; such metabolic distinctions have largely been restricted to molecular studies or classical metabolomics (49, 59). Although mass cytometry can simultaneously detect ~40 parameters per panel, the vaporization of analyzed cells prevents further study of the precise subsets identified, which remains the advantage of FACS.

## Microfluidics


Microfluidic single cell assays essentially miniaturize existing techniques to assess ASC secretions, to increase the scale and throughput of analyses and enable single cell resolution *via* compartmentalization into either wells or droplets (14, 15). Miniaturization also allows for greatly reduced reagent usage and less cells are needed per experiment. The functional measurements within microfluidic ASC assays largely share the concept of capturing secreted antibody or cytokine onto a physical surface followed by visualization with fluorescent detection reagents. The advantages of microfluidic-based functional analyses of ASC include their direct identification of ASC *via* antibody secretion, a high throughput, and the ability to absolutely quantify ASC secretions over time.

Micro- and nano-well microfluidic approaches use microfabrication techniques to create thousands of wells into which individual ASC can be introduced (60–62). The nature of the wells and coating and reagent strategy used can be readily customized to assay different antibodies, antigens, or secretions. The small volumes of these wells allow for absolute quantification of secreted molecules, in contrast to ELISpot where only relative measurements can be made (14). Well-based microfluidic assays also have lower detection thresholds than ELISpot, making them more sensitive and more capable of wholly representing ASC (63). Importantly, as ASC are identified and sustained within the static well array, cells can be recovered following the assay for additional functional or molecular assessment. The Berkeley Lights “nanopen” platform introduces considerable advancement to well-based ASC assays using optofluidics, offering integrated workflows for antibody screening of ASC followed by targeted recovery of specific cells for molecular analysis (64). This rapid pipeline for functional antibody assessment was recently used to characterize antibody repertoires following SARS-COV2 infection (65). Despite their advantages over ELISpot, well-based microfluidic assays have seen limited application beyond

technical demonstrations and antibody discovery (66–68), mainly due to their cost and limited throughput.

Droplet microfluidics achieves single cell compartmentalization using two immiscible fluids, an aqueous phase containing the cell and assay reagents and an oil phase that separates the aqueous phase into droplets with single cells (14). Large numbers of droplets can be quickly produced for each new sample and the assay composition can be easily changed. Secretion by encapsulated ASC is assessed by beads or other cells within the droplet that act as capture surfaces for secreted cytokine or antibody, to which fluorescent reagents in the droplet can localize for measurement. Flow-based or flowed droplet assays can characterize ASC with high throughput by passing droplets at high frequency through a laser for rapid detection of fluorescence relocation within droplets (69–71). Droplet measurement may also be paired with dielectrophoretic sorting, which pushes or pulls droplets into separate channels by manipulating electric fields, allowing for further assessment of directly identified ASC or antigen-specific ASC (69, 72). We reported in Gerard et al (69) the CelliGo assay using a double fluorescent sandwich ELISA in microfluidic droplets for the identification, sorting, and  $V_H$ - $V_L$  sequencing of antigen-specific IgG antibodies produced by ASC from immunized mice. In this study, we demonstrated screening of a bacterial antigen (tetanus toxoid), an autoantigen linked to Rheumatoid Arthritis (Glucose-6-phosphate Isomerase), and an insoluble, membrane-expressed antigen (tetraspanin-8; TSPAN8); antigen-specific ASC against all 3 model antigens were able to be sorted by this flowed droplet microfluidic technique.

An alternative approach to study ASC in droplets is to collect droplets in a horizontal plane and measure changes in droplet fluorescence over multiple timepoints, termed a stationary droplet-assay (14) or DropMap (73, 74). DropMap measures fluorescence relocation to a central line of antibody-capturing beads aligned using a magnetic field within each droplet. Both secreted antibody relocation and soluble antigen relocation to the beadline are measured. The ability to measure relocation over time within DropMap allows for the determination of both antibody affinity and secretion rate, in addition to determining the proportion of antigen-specific and total ASC within a sample as with other microfluidic techniques. DropMap has been applied to investigate the physiology of ASC in viral infection (75), autoimmunity (74), and fundamental ASC biology (73, 76). In our view, DropMap offers a major advancement in current capabilities to functionally characterize ASC, particularly for defining the specificity and affinity repertoire of ASC. An example alternative strategy to DropMap for affinity repertoire mapping is to sort large numbers of B cells or ASC for their BCR sequences, followed by gene synthesis or direct cloning, re-expression, and kinetic analysis of these antibodies by a technique such as bio-layer interferometry (BLI) (77–79) (**Figure 2**); this approach is significantly more complex, costly, and time consuming than DropMap. Recently however, we reported antigen-specific single cell memory B cell *in vitro* differentiation into ASC that allowed for fast and large scale (~400) affinity measurements by BLI from culture supernatants without costly antibody re-expression (80). Initial sorting for



**FIGURE 2** | Comparison of DropMap vs a classical pipeline to define affinity repertoires. The affinity repertoire of ASC towards a given antigen is an important metric for the quality of the ASC response. ASC are commonly isolated from the spleen, bone marrow, or blood of donor/patients or experimental animals. The DropMap assay (top) offers a platform that within 1 hour can return the affinity repertoire in a single assay, as well as the IgG secretion rate and frequency of ASC according to direct *ex vivo* measurement (refer to main text for details); this approach is limited by requiring ASC to secrete antibodies at the time of data acquisition, data can only be acquired once, and afterwards cells of interest are lost. An alternative strategy (bottom) to yield a similar affinity repertoire first requires cell isolation by FACS, followed by  $V_H$  and  $V_L$  targeted RT-PCR (& BCR-seq if required) and cloning into an expression vector, transfection of the vector into an expression system and cell culture, purification and finally assessment of the recombinant expressed antibody by BLI or SPR; this pipeline requires 1½ -2 weeks to complete, is significantly more complex and costly, and can only assess  $V_H$ - $V_L$  pairs that could be successfully amplified, cloned and expressed as recombinant antibodies.

ASC may also bias the antibody repertoire through restrictive FACS gating strategies unless a direct functional assay is used prior to directly select for ASC, whereas DropMap offers an unbiased screen of PBMCs or an enriched B cell pool for ASC. Another novel approach involving BCR sequencing paired with liquid chromatography–tandem mass spectrometry proteomics (81, 82) allows for unbiased molecular assessment of antibodies from the serum, but requires infrastructure and specialist supervision, and is currently largely restricted to the most represented antibodies in the serum.

The major limitation to widespread adoption of functional, droplet-based assays of ASC is their bespoke nature. Although droplet microfluidics is a growing field, with most reagents commercially available, labs must produce their own consumables for droplet production and the apparatus for assay observation, which require specialized equipment and expertise.

## MOLECULAR ANALYSES

The molecular basis for the behavior of ASC is equally important to understanding ASC physiology. The molecular aspects of ASC most investigated are (i) the heavy and light chain variable regions ( $V_H$  and  $V_L$ ) sequences, formed by gene rearrangements and sequence diversification mechanisms (83), encoding the antigen binding domains of antibodies and (ii) the transcriptional profile of ASCs; these aspects may be probed using bulk  $V_H$ -seq or RNAseq, BCR-seq, and increasingly now single-cell RNAseq (scRNAseq) following either single-cell ASC

FACS into 96 or 384 well plates, or microfluidic droplet-based barcoded scRNAseq (e.g., 10xGenomics Chromium). Importantly, BCR sequences can be computationally inferred from scRNA-seq data using open-source libraries (e.g. BraCeR (84), VDJPuzzle (85)), linking antibody sequence (i.e., genotype, clonal information) to transcriptome phenotype. Recent advances on ASC characterization using RNAseq, ATAC-seq and ChIP-seq have been reviewed elsewhere (86), as well as molecular mechanisms leading to plasma cell differentiation from the germinal center reaction (87). Glaros et al (38) highlight the capacity for scRNAseq to identify B cell subsets and observe shifts in differentiation, identifying antigen availability as a key regulator of the plasmablast response.

A common strategy for molecular ASC clonal identification is bulk sequencing of  $V_H$  regions (37), which allows for large numbers of cells to be assayed without the cost and limitations imposed by a need for single cell approaches. However, the  $V_L$  sequence information is lost, and it is not possible to re-express the original antibody recombinantly. Alternatively, Price et al (37) recently used bulk RNAseq to identify unique transcriptional profiles for IgG, IgM, and IgA ASC subsets, with the ability to assess both clonality and gene expression. Such approaches offer insight into the clonal diversity of ASC responses but have less resolution than paired  $V_H$ - $V_L$  chain sequencing and have no possibility for functional assessment of clones within the antibody repertoire. When the full  $V_H$ - $V_L$  sequence is required, single-cell approaches are required, and currently available techniques for HT BCRseq have been reviewed by Curtis and Lee (88), who highlight advances in  $V_H$

and  $V_L$  chain pairing by barcoding (69) or linkage as well as increased cell-throughput through the use of microfluidics. Moreover, techniques such as LIBRA-seq (89) or CelliGo (69) allow for assessment of antigen specificity or antigen specificity coupled to antibody secretion, respectively, integrated within their BCRseq pipelines. Wang et al (90) used microfluidics to compartmentalize human plasmablasts as single cells and generate paired  $V_H$ - $V_L$  repertoires for direct Fab display on yeast and functional assessment. Notably, Jiang et al (91) utilized a combination of bulk  $V_H$ -seq, BCRseq, and full scRNAseq to identify autoreactive ASC persisting after treatment with rituximab. Such an approach leverages the complexity and throughput of each technique with the depth of information required to address the authors' underlying question, saving considerable time, and lowering costs overall. Using the 10x genomics technology, integrating emulsion-based single cell separation with barcoded RNAseq (Chromium), plasmablast-derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine were characterized for antigen specificity, epitope mapping and neutralization potential (92).

A final molecular approach worth mentioning is the use of mass spectrometry to assess the relative abundance of specific antibodies in serum or a tissue sample, known as Ab-seq (93). Pairing Ab-seq with any of the RNA-seq approaches above allows for inferences to be made regarding the contribution of specific ASC clones to the polyclonal ASC response, providing invaluable insight into the immunological relevance of ASC clonal diversity. Lee et al (94) utilized Ab-seq to identify potently neutralizing antibodies and ASC clones persisting across multiple exposures to influenza. Ab-seq has also been applied in similar studies for antibodies against norovirus (95) and HIV-1 (96).

## DISCUSSION

### Multiplexing Is the Future for High Throughput Single ASC Analyses

The availability of high throughput methods for the study of ASC at the single cell level has progressed immensely for both functional and molecular characterization. Considerable progress has been made in understanding ASC development and differentiation, but with limited information regarding the relationships between population surface marker expression, transcriptional and metabolic activity, and the functional "quality" of the ASC (affinity, specificity, secretion rate).

The presence of immunoglobulins within all plasmablasts or plasma cells does not exclude the possibility for significant stratification of secretion rates from high to nearly

undetectable. As we showed in Eyer et al. (73), antibody secretion by a seemingly homogenous population of ASC may vary by several orders of magnitude. The causes of such secretory diversity remain poorly understood. Current techniques for direct measurement of single cell immunoglobulin secretion (spot- and microfluidic-based assays) are currently unable to distinguish precise B cell populations alone. ASC identified and isolated from direct functional assays have not been assessed afterwards with higher parameter techniques such as flow and mass cytometry or scRNAseq, to interrogate the source of this secretory diversity.

Ultimately, investigations of ASC physiology should strive to employ a combination of the techniques discussed. In the context of antibodies, with only a repertoire of  $V_H$ - $V_L$  sequences the contribution and quality of a given antibody to the humoral immune response is difficult to appreciate. Likewise, knowing the affinity or neutralization repertoire of antibodies from ASC without knowing their clonality and molecular basis limits insight into ASC population dynamics and distribution.

Evolution of the existing and emerging methods for HT ASC phenotypic characterization to readily integrate with the various single cell molecular techniques should be an immediate goal to overcome current limitations. HT single cell molecular (scRNA-seq) techniques are becoming more accessible and affordable, with great efforts to increase the fidelity and ease of analysis. HT single cell assays will be central to unravelling how ASC phenotypic markers relate to their developmental stage, antibody affinity, and antibody or cytokine secretion rate, and to what degree these elements are interrelated.

## AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

## FUNDING

PB acknowledges funding from the French National Research Agency grant ANR-14-CE16-0011 project *DROPmAbs* and ANR-18-CE15-0001 project *Autoimmuni-B*, by the Institut Carnot Pasteur Microbes et Santé (ANR 11 CARN 0017-01), the Institut Pasteur and the Institut National de la Santé et de la Recherche Médicale (INSERM). MB is a recipient of a CIFRE fellowship from the French Association Nationale de la Recherche et de la Technologie (ANRT). None of the sources of funding have an interest in the subject matter or materials discussed in the submitted manuscript.

## REFERENCES

1. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The Generation of Antibody-Secreting Plasma Cells. *Nat Rev Immunol* (2015) 15(3):160–71. doi: 10.1038/nri3795

2. Shlomchik MJ, Weisel F. Germinal Center Selection and the Development of Memory B and Plasma Cells. *Immunol Rev* (2012) 247(1):52–63. doi: 10.1111/j.1600-065X.2012.01124.x
3. Di Niro R, Lee SJ, Vander Heiden JA, Elsner R, Trivedi N, Bannock J. SalmOnella Infection Drives Promiscuous B Cell Activation Followed By

- Extrafollicular Affinity Maturation. *Immunity* (2015) 43(1):120–131. doi: 10.1016/j.immuni.2015.06.013
4. Allman D, Wilmore JR, Gaudette BT. The Continuing Story of T-Cell Independent Antibodies. *Immunol Rev* (2019) 288(1):128–35. doi: 10.1111/imr.12754
  5. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt E, Rosenwald A, et al. Blimp-1 Orchestrates Plasma Cell Differentiation by Extinguishing the Mature B Cell Gene Expression Program. *Immunity* (2002) 17(1):51–62. doi: 10.1016/S1074-7613(02)00335-7
  6. Lightman SM, Utley A, Lee KP. Survival of Long-Lived Plasma Cells (LLPC): Piecing Together the Puzzle. *Front Immunol* (2019) 10:965. doi: 10.3389/fimmu.2019.00965
  7. Cordero H, King RG, Dogra P, Dufeu C, See S, Chong A, et al. Intrathymic Differentiation of Natural Antibody-Producing Plasma Cells in Human Neonates. *Nat Commun* (2021) 12(1):5761. doi: 10.1038/s41467-021-26069-2
  8. Nuñez S, Moore C, Gao B, Rogers K, Hidalgo Y, Del Nido P, et al. The Human Thymus Perivascular Space is a Functional Niche for Viral-Specific Plasma Cells. *Sci Immunol* (2016) 1(6). doi: 10.1126/sciimmunol.aah4447
  9. Hauser AE, Debes GF, Arce S, Casese G, Hamann A, Radbruch A, et al. Chemotactic Responsiveness Toward Ligands for CXCR3 and CXCR4 Is Regulated on Plasma Blasts During the Time Course of a Memory Immune Response. *J Immunol* (2002) 169(3):1277–82. doi: 10.4049/jimmunol.169.3.1277
  10. Chang HD, Tokoyoda K, Hoyer B, Alexander T, Khodadadi L, Mei H, et al. Pathogenic Memory Plasma Cells in Autoimmunity. *Curr Opin Immunol* (2019) 61:86–91. doi: 10.1016/j.coi.2019.09.005
  11. Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. *Front Immunol* (2020) 11:610688. doi: 10.3389/fimmu.2020.610688
  12. Pioli PD. Plasma Cells, the Next Generation: Beyond Antibody Secretion. *Front Immunol* (2019) 10:2768. doi: 10.3389/fimmu.2019.02768
  13. Upasani V, Id IR, Id TC, Rodenhuis-Zybert I, Cantaert T. Antibody-Independent Functions of B Cells During Viral Infections. *PLoS Pathog* (2021) 17(7):e1009708. doi: 10.1371/journal.ppat.1009708
  14. Bucheli OTM, Sigvaldadóttir I, Eyer K. Measuring Single-Cell Protein Secretion in Immunology: Technologies, Advances, and Applications. *Eur J Immunol* (2021) 51(6):1334–47. doi: 10.1002/eji.202048976
  15. Jammes FC, Maerk SJ. How Single-Cell Immunology is Benefiting From Microfluidic Technologies. *Microsystems Nanoeng* (2020) 6(1):45. doi: 10.1038/s41378-020-0140-8
  16. Tzeng SJ. The Isolation, Differentiation, and Quantification of Human Antibody-Secreting B Cells From Blood: Elispot as a Functional Readout of Humoral Immunity. *J Vis Exp* (2016) 2016(118):e54582. doi: 10.3791/54582
  17. Janetzki S, Rueger M, Dillenbeck T. Stepping Up ELISpot: Multi-Level Analysis in FluoroSpot Assays. *Cells* (2014) 3(4):1102–15. doi: 10.3390/cells3041102
  18. Meyer Sauter PM, Seiler M, Trück J, Unger WWJ, Paioni P, Rely C, et al. Diagnosis of Mycoplasma Pneumoniae Pneumonia With Measurement of Specific Antibody-Secreting Cells. *Am J Respir Crit Care Med* (2019) 200(8):1066–9. doi: 10.1164/rccm.201904-0860LE
  19. Carter MJ, Mitchell RM, Sauter PM, Kelly DF, Trück J. The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications. *Front Immunol* (2017) 8:630. doi: 10.3389/fimmu.2017.00630
  20. Lima-Junior J, Morgado F, Conceição-Silva F. How Can Elispot Add Information to Improve Knowledge on Tropical Diseases? *Cells* (2017) 6(4):31. doi: 10.3390/cells6040031
  21. Faresjö M. Enzyme Linked Immuno-Spot; a Useful Tool in the Search for Elusive Immune Markers in Common Pediatric Immunological Diseases. *Cells* (2012) 1(2):141–52. doi: 10.3390/cells1020141
  22. Mahévas M, Michel M, Weill JC, Reynaud CA. Long-Lived Plasma Cells in Autoimmunity: Lessons From B-Cell Depleting Therapy. *Front Immunol* (2013) 4:494(DEC). doi: 10.3389/fimmu.2013.00494
  23. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen Is a Primary Site for Activation of Platelet-Reactive T and B Cells in Patients With Immune Thrombocytopenic Purpura. *J Immunol* (2002) 168(7):3675–82. doi: 10.4049/jimmunol.168.7.3675
  24. Saletti G, Çuburu N, Yang JS, Dey A, Czerkinsky C. Enzyme-Linked Immunospot Assays for Direct Ex Vivo Measurement of Vaccine-Induced Human Humoral Immune Responses in Blood. *Nat Protoc* (2013) 8(6):1073–87. doi: 10.1038/nprot.2013.058
  25. Bonezi V, Cataneo AHD, Branquinho MSF, Silva M, Gonzalez-Dias P, Pereira S, et al. Flavivirus-Mediating B Cell Differentiation Into Antibody-Secreting Cells in Humans Is Associated With the Activation of the Tryptophan Metabolism. *Front Immunol* (2020) 11:20. doi: 10.3389/fimmu.2020.00020
  26. Cossarizza A, Chang HD, Radbruch A, Acs A, Adam D, Adam-Klages S, et al. Guidelines for the Use of Flow Cytometry and Cell Sorting in Immunological Studies (Second Edition). *Eur J Immunol* (2019) 49(10):1457–973. doi: 10.1002/eji.201970107
  27. Boonyaratankornkit J, Taylor JJ. Techniques to Study Antigen-Specific B Cell Responses. *Front Immunol* (2019) 10:1694. doi: 10.3389/fimmu.2019.01694
  28. Ellebedy AH, Jackson KJL, Kissick HT, Nakaya H, Davis C, Roskin K, et al. Defining Antigen-Specific Plasmablast and Memory B Cell Subsets in Blood Following Viral Infection and Vaccination of Humans. *Nat Immunol* (2016) 17(10):1226. doi: 10.1038/NI.3533
  29. Quách TD, Rodríguez-Zhurbenko N, Hopkins TJ, Guo X, Hernández A, Li W, et al. Distinctions Among Circulating Antibody-Secreting Cell Populations, Including B-1 Cells, in Human Adult Peripheral Blood. *J Immunol* (2016) 196(3):1060–9. doi: 10.4049/jimmunol.1501843
  30. Carrell J, Groves CJ. OMIP-043: Identification of Human Antibody Secreting Cell Subsets. *Cytom Part A*. (2018) 93(2):190–3. doi: 10.1002/cyto.a.23305
  31. Sanz I, Wei C, Jenks SA, Cashman K, Tipton C, Woodruff M, et al. Challenges and Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations. *Front Immunol* (2019) 10:2458(OCT). doi: 10.3389/fimmu.2019.02458
  32. Landsverk OJB, Snir O, Casado RB, Richter L, Mold J, Réu P, et al. Antibody-Secreting Plasma Cells Persist for Decades in Human Intestine. *J Exp Med* (2017) 214(2):309–17. doi: 10.1084/JEM.20161590
  33. Paiva B, Puig N, Cedena MT, de Jong B, Ruiz Y, Rapado I, et al. Differentiation Stage of Myeloma Plasma Cells: Biological and Clinical Significance. *Leukemia* (2017) 31(2):382–92. doi: 10.1038/leu.2016.211
  34. Blanc P, Moro-Sibilot L, Barthly L, Jagot F, This S, de Bernard S, et al. Mature IgM-Expressing Plasma Cells Sense Antigen and Develop Competence for Cytokine Production Upon Antigenic Challenge. *Nat Commun* (2016) 7:13600. doi: 10.1038/ncomms13600
  35. Pinto D, Montani E, Bolli M, Garavaglia G, Sallusto F, Lanzavecchia A, et al. A Functional BCR in Human IgA and IgM Plasma Cells. *Blood* (2013) 121(20):4110–4. doi: 10.1182/BLOOD-2012-09-459289
  36. Pinder CL, Kratochvil S, Cizmeci D, Muir L, Guo Y, Shattock R, et al. Isolation and Characterization of Antigen-Specific Plasmablasts Using a Novel Flow Cytometry-Based Ig Capture Assay. *J Immunol* (2017) 199(12):4180–8. doi: 10.4049/jimmunol.1701253
  37. Price MJ, Hicks SL, Bradley JE, Randall TD, Boss JM, Scharer CD. IgM, IgG, and IgA Influenza-Specific Plasma Cells Express Divergent Transcriptomes. *J Immunol* (2019) 203(8):2121–9. doi: 10.4049/JIMMUNOL.1900285
  38. Glaros V, Rauschmeier R, Artemov AV, Reinhardt A, Ols S, Emmanouilidi A, et al. Limited Access to Antigen Drives Generation of Early B Cell Memory While Restraining the Plasmablast Response. *Immunity* (2021) 54(9):2005–2023.e10. doi: 10.1016/j.immuni.2021.08.017
  39. Franz B, May KF, Dranoff G, Wucherpfennig K. Ex Vivo Characterization and Isolation of Rare Memory B Cells With Antigen Tetramers. *Blood* (2011) 118(2):348. doi: 10.1182/BLOOD-2011-03-341917
  40. Llinàs L, Lázaro A, de Salort J, Matesanz-Isabel J, Sintés J, Engel P. Expression Profiles of Novel Cell Surface Molecules on B-Cell Subsets and Plasma Cells as Analyzed by Flow Cytometry. *Immunol Lett* (2011) 134(2):113–21. doi: 10.1016/j.imlet.2010.10.009
  41. Scharer CD, Patterson DG, Mi T, Price MJ, Hicks SL, Boss JM. Antibody-Secreting Cell Destiny Emerges During the Initial Stages of B-Cell Activation. *Nat Commun* (2020) 11:3989. doi: 10.1038/s41467-020-17798-x
  42. Mahévas M, Patin P, Huetz F, Descatoire M, Cagnard N, Bole-Feysot C, et al. B Cell Depletion in Immune Thrombocytopenia Reveals Splenic Long-Lived Plasma Cells. *J Clin Invest* (2013) 123(1):432–42. doi: 10.1172/JCI65689
  43. Xu M, Jiang Y, Wang J, Liu J, Liu C, Liu D, et al. Distinct Variations of Antibody Secreting Cells and Memory B Cells During the Course of Kawasaki Disease. *BMC Immunol* (2019) 20(1):16. doi: 10.1186/s12865-019-0299-7
  44. Tipton CM, Fucile CF, Darce J, Chida A, Ichikawa T, Gregoretti I, et al. Diversity, Cellular Origin and Autoreactivity of Antibody-Secreting Cell Population Expansions in Acute Systemic Lupus Erythematosus. *Nat Immunol* (2015) 16(7):755–65. doi: 10.1038/ni.3175



45. Jin W, Luo Z, Yang H. Review Article Peripheral B Cell Subsets in Autoimmune Diseases: Clinical Implications and Effects of B Cell-Targeted Therapies. *J Immunol Res* (2020) 2020:9518137. doi: 10.1155/2020/9518137. Published online.
46. Woodruff MC, Ramonell RP, Nguyen DC, Cashman K, Saini A, Haddad N, et al. Extrafollicular B Cell Responses Correlate With Neutralizing Antibodies and Morbidity in COVID-19. *Nat Immunol* 2020 2112 (2020) 21(12):1506–16. doi: 10.1038/s41590-020-00814-z
47. Ramadani F, Bowen H, Upton N, Hobson P, Chan Y, Chen J, et al. Ontogeny of Human IgE-Expressing B Cells and Plasma Cells. *Allergy Eur J Allergy Clin Immunol* (2017) 72(1):66–76. doi: 10.1111/all.12911
48. Nguyen DC, Lewis HC, Joyner C, Warren V, Xiao H, Kissick H, et al. Extracellular Vesicles From Bone Marrow-Derived Mesenchymal Stromal Cells Support Ex Vivo Survival of Human Antibody Secreting Cells. *J Extracell Vesicles* (2018) 7(1):1463778. doi: 10.1080/20013078.2018.1463778
49. Nguyen DC, Joyner CJ, Sanz I, Lee FEH. Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells. *Front Immunol* (2019) 10:2138. doi: 10.3389/fimmu.2019.02138
50. Auladell M, Nguyen TH, Garcillán B, Mackay F, Kedzierska K, Fox A. Distinguishing Naive- From Memory-Derived Human B Cells During Acute Responses. *Clin Transl Immunol* (2019) 8(11):e01090. doi: 10.1002/cti.21090
51. Doucett VP, Gerhard W, Owler K, Curry D, Brown L, Baumgarth N. Enumeration and Characterization of Virus-Specific B Cells by Multicolor Flow Cytometry. *J Immunol Methods* (2005) 303(1-2):40–52. doi: 10.1016/j.jim.2005.05.014
52. Di Niro R, Mesin L, Raki M, Zheng N, Lund-Johansen F, Lundin K, et al. Rapid Generation of Rotavirus-Specific Human Monoclonal Antibodies From Small-Intestinal Mucosa. *J Immunol* (2010) 185(9):5377–83. doi: 10.4049/jimmunol.1001587
53. Tellier J, Nutt SL. Standing Out From the Crowd: How to Identify Plasma Cells. *Eur J Immunol* (2017) 47(8):1276–9. doi: 10.1002/eji.201747168
54. Fooksman DR, Schwickert TA, Victoria GD, Dustin ML, Nussenzweig MC, Skokos D. Development and Migration of Plasma Cells in the Mouse Lymph Node. *Immunity* (2010) 33(1):118–27. doi: 10.1016/j.immuni.2010.06.015
55. Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran L, Hodgkin P, et al. Plasma Cell Ontogeny Defined by Quantitative Changes in Blimp-1 Expression. *J Exp Med* (2004) 200(8):967–77. doi: 10.1084/jem.20040973
56. Arumugakani G, Stephenson SJ, Newton DJ, Rawstron A, Emery P, Doody G, et al. Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. *J Immunol* (2017) 198(12):4618–28. doi: 10.4049/jimmunol.1501761
57. Glass DR, Tsai AG, Oliveria JP, Hartmann F, Kimmey S, Calderon A, et al. An Integrated Multi-Omic Single-Cell Atlas of Human B Cell Identity. *Immunity* (2020) 53(1):217–32.e5. doi: 10.1016/j.immuni.2020.06.013
58. Hartmann FJ, Mrdjen D, McCaffrey E, Glass D, Greenwald N, Bharadwaj A, et al. Single-Cell Metabolic Profiling of Human Cytotoxic T Cells. *Nat Biotechnol* 2020 392 (2020) 39(2):186–97. doi: 10.1038/s41587-020-0651-8
59. Guo M, Price MJ, Patterson DG, Barwick B, Haines R, Kania A, et al. EZH2 Represses the B Cell Transcriptional Program and Regulates Antibody-Secreting Cell Metabolism and Antibody Production. *J Immunol* (2018) 200(3):1039–52. doi: 10.4049/jimmunol.1701470
60. Han Q, Bradshaw EM, Nilsson B, Haflercd DA, Love JC. Multidimensional Analysis of the Frequencies and Rates of Cytokine Secretion From Single Cells by Quantitative Microengraving. *Lab Chip* (2010) 10(11):1391–400. doi: 10.1039/B926849A
61. Zhu H, Stybayeva G, Silangcruz J, Yan J, Ramanculov E, Dandekar S, et al. Detecting Cytokine Release From Single T-Cells. *Anal Chem* (2009) 81(19):8150–6. doi: 10.1021/AC901390J
62. Torres AJ, Hill AS, Love JC. Nanowell-Based Immunoassays for Measuring Single-Cell Secretion: Characterization of Transport and Surface Binding. *Anal Chem* (2014) 86(23):11562–9. doi: 10.1021/AC4030297
63. Rybczynska M, Baudry J, Klaus E. The Impact of Frost-Damage on the Quality and Quantity of the Secreted Antigen-Specific IgG Repertoire. *Vaccine* (2020) 38(33):5337–42. doi: 10.1016/j.vaccine.2020.05.066
64. Winters A, McFadden K, Bergen J, Landas J, Berry K, Gonzalez A, et al. Rapid Single B Cell Antibody Discovery Using Nanopens and Structured Light. *MAbs* (2019) 11(6):1025. doi: 10.1080/19420862.2019.1624126
65. Zost SJ, Gilchuk P, Chen RE, Case J, Reidy J, Trivette A, et al. Rapid Isolation and Profiling of a Diverse Panel of Human Monoclonal Antibodies Targeting the SARS-CoV-2 Spike Protein. *Nat Med* (2020) 26(9):1422. doi: 10.1038/s41591-020-0998-X
66. Ogunniyi AO, Story CM, Papa E, Guillen E, Love JC. Screening Individual Hybridomas by Microengraving to Discover Monoclonal Antibodies. *Nat Protoc* (2009) 4(5):767–82. doi: 10.1038/NPROT.2009.40
67. Ogunniyi AO, Thomas BA, Politano TJ, Varadarajan N, Landais E, Poignard P, et al. Profiling Human Antibody Responses by Integrated Single-Cell Analysis. *Vaccine* (2014) 32(24):2866–73. doi: 10.1016/j.vaccine.2014.02.020
68. Story CM, Papa E, Hu CC, Ronan JL, Herlihy K, Ploegh HL, et al. Profiling Antibody Responses by Multiparametric Analysis of Primary B Cells. *Proc Natl Acad Sci U S A* (2008) 105(46):17902–7. doi: 10.1073/PNAS.0805470105
69. Gérard A, Woolfe A, Mottet G, Reichen M, Castrillon C, Menrath V, et al. High-Throughput Single-Cell Activity-Based Screening and Sequencing of Antibodies Using Droplet Microfluidics. *Nat Biotechnol* (2020) 38(6):715–21. doi: 10.1038/s41587-020-0466-7
70. Matutis L, Gilbert J, Ung WL, Weitz DA, Griffiths AD, Heyman JA. Single-Cell Analysis and Sorting Using Droplet-Based Microfluidics. *Nat Protoc* (2013) 8(5):870–91. doi: 10.1038/NPROT.2013.046
71. Ding R, Hung KC, Mitra A, Ung L, Lightwood D, Tu R, et al. Rapid Isolation of Antigen-Specific B-Cells Using Droplet Microfluidics. *RSC Adv* (2020) 10(45):27006–13. doi: 10.1039/d0ra04328a
72. Shembekar N, Hu H, Eustace D, Merten CA. Single-Cell Droplet Microfluidic Screening for Antibodies Specifically Binding to Target Cells. *Cell Rep* (2018) 22(8):2206–15. doi: 10.1016/j.celrep.2018.01.071
73. Eyer K, Doineau RCL, Castrillon CE, Briseño-Roa L, Menrath V, Mottet G, et al. Single-Cell Deep Phenotyping of IgG-Secreting Cells for High-Resolution Immune Monitoring. *Nat Biotechnol* (2017) 35(10):977–82. doi: 10.1038/nbt.3964
74. Canales-Herrerias P, Crickx E, Broketa M, Sokal A, Chenon G, Azzaoui I, et al. Single-Cell Analyses of Immune Thrombocytopenic Patients Reveal Multiorgan Dissemination of High-Affinity Autoreactive Plasma Cells. *bioRxiv* (2021) 2021.06.29.450355. doi: 10.1101/2021.06.29.450355
75. Kräutler NJ, Yermanos A, Pedrioli A, Welten S, Lorgé D, Greczmiel U, et al. Quantitative and Qualitative Analysis of Humoral Immunity Reveals Continued and Personalized Evolution in Chronic Viral Infection. *Cell Rep* (2020) 30(4):997–1012.e6. doi: 10.1016/j.celrep.2019.12.088
76. Eyer K, Castrillon C, Chenon G, Bibette J, Bruhns P, Griffiths A, et al. The Quantitative Assessment of the Secreted IgG Repertoire After Recall to Evaluate the Quality of Immunizations. *J Immunol* (2020) 205(4):1176–84. doi: 10.4049/jimmunol.2000112
77. Alanine DGW, Quinkert D, Kumarasingha R, Gilson PR, Higgins MK, Draper Correspondence SJ. Human Antibodies That Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies. *Cell* (2019) 178:216–228.e21. doi: 10.1016/j.cell.2019.05.025
78. Viant C, Weymar GHJ, Escolano A, Cipolla M, Gazumyan A, Correspondence MCN. Antibody Affinity Shapes the Choice Between Memory and Germinal Center B Cell Fates. *Cell* (2020) 183:1298–1311.e11. doi: 10.1016/j.cell.2020.09.063
79. Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, et al. Isolation of Potent Neutralizing Antibodies From a Survivor of the 2014 Ebola Virus Outbreak. *Science* (2016) 351(6277):1078–83. doi: 10.1126/SCIENCE.AAD5788
80. Sokal A, Barba-Spaeth G, Fernández I, Broketa M, Azzaoui I, de la Selle A, et al. mRNA Vaccination of Naive and COVID-19-Recovered Individuals Elicits Potent Memory B Cells That Recognize SARS-CoV-2 Variants. *Immunity* (2021) 54(12):2893–907.e5. doi: 10.1016/j.immuni.2021.09.011
81. Williams LD, Ofek G, Schätzle S, McDaniel J, Lu X, Nicely N, et al. Potent and Broad HIV-Neutralizing Antibodies in Memory B Cells and Plasma. *Sci Immunol* (2017) 2(7):27. doi: 10.1126/SCIIMMUNOL.AAL2200
82. Lee J, Boutz DR, Chromikova V, Joyce M, Vollmers C, Leung K, et al. Molecular-Level Analysis of the Serum Antibody Repertoire in Young Adults Before and After Seasonal Influenza Vaccination. *Nat Med* 2016 2212. (2016) 22(12):1456–64. doi: 10.1038/nm.4224
83. Rees AR. Understanding the Human Antibody Repertoire. *mAbs* (2020) 12(1):e1729683. doi: 10.1080/19420862.2020.1729683

84. Lindeman I, Emerton G, Mamanova L, Snir O, Polanski K, Qiao S, et al. BraCeR: B-Cell-Receptor Reconstruction and Clonality Inference From Single-Cell RNA-Seq. *Nat Methods* 2018 15(8):563–5. doi: 10.1038/s41592-018-0082-3
85. Rizzetto S, Koppstein DNP, Samir J, Singh M, Reed J, Cai C, et al. B-Cell Receptor Reconstruction From Single-Cell RNA-Seq With VDJpuzzle. *Bioinformatics* (2018) 34(16):2846–7. doi: 10.1093/BIOINFORMATICS/BTY203
86. Delaloy C, Schuh W, Jäck H-M, Bonaud A, Espéli M. Single Cell Resolution of Plasma Cell Fate Programming in Health and Disease. *Eur J Immunol* (2021). doi: 10.1002/EJL.202149216
87. Ise W, Kurosaki, Tomohiro, Kurosaki T. Plasma Cell Differentiation During the Germinal Center Reaction. *Immunol Rev* (2019) 288:64–74. doi: 10.1111/imr.12751
88. Curtis NC, Lee J. Beyond Bulk Single-Chain Sequencing: Getting at the Whole Receptor. *Curr Opin Syst Biol* (2020) 24:93–9. doi: 10.1016/j.coisb.2020.10.008
89. Setliff I, Shiakolas AR, Pilewski KA, Murji A, Mapengo R, Janowska K, et al. High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. *Cell* (2019) 179(7):1636–1646.e15. doi: 10.1016/j.cell.2019.11.003
90. Wang B, Dekosky BJ, Timm MR, Lee J, Normandin E, Misasi J, et al. Functional Interrogation and Mining of Natively Paired Human VH:VL Antibody Repertoires. *Nature Biotechnol* (2018) 36:152–5. doi: 10.1038/nbt.4052
91. Jiang R, Fichtner ML, Hoehn KB, Pham M, Stathopoulos P, Nowak R, et al. Single-Cell Repertoire Tracing Identifies Rituximab-Resistant B Cells During Myasthenia Gravis Relapses. *JCI Insight* (2020) 5(14):e136471. doi: 10.1172/JCI.INSIGHT.136471
92. Amanat F, Thapa M, Lei T, Ahmed S, Adelsberg D, Carreño J, et al. SARS-CoV-2 mRNA Vaccination Induces Functionally Diverse Antibodies to NTD, RBD, and S2. *Cell* (2021) 184(15):3936–48.e10. doi: 10.1016/j.cell.2021.06.005
93. Snapkov I, Chernigovskaya M, Sinitcyn P, Lê Quý K, Nyman TA, Greiff V. Progress and Challenges in Mass Spectrometry-Based Analysis of Antibody Repertoires. *Trends Biotechnol* (2021). doi: 10.1016/j.tibtech.2021.08.006
94. Lee J, Paparoditis P, Horton AP, Frühwirth A, McDaniel J, Jung J, et al. Persistent Antibody Clonotypes Dominate the Serum Response to Influenza Over Multiple Years and Repeated Vaccinations. *Cell Host Microbe* (2019) 25(3):367–76.e5. doi: 10.1016/j.chom.2019.01.010
95. Lindesmith LC, McDaniel JR, Changela A, Verardi R, Kerr S, Costantini V, et al. Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses After Human Norovirus Vaccination. *Immunity* (2019) 50(6):1530–41.e8. doi: 10.1016/j.immuni.2019.05.007
96. Sajadi MM, Dashti A, Rikhtegaran Tehrani Z, Tolbert W, Seaman M, Ouyang X, et al. Identification of Near-Pan-Neutralizing Antibodies Against HIV-1 by Deconvolution of Plasma Humoral Responses. *Cell* (2018) 173(7):1783–95.e14. doi: 10.1016/j.cell.2018.03.061

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. PB is a paid consultant to Regeneron Pharmaceuticals. MB declares that he has no relevant conflicts of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Broketa and Bruhns. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.